版本:
中国

BRIEF-Kite Pharma announces exclusive license with NIH for Solid Tumor treatment

Sept 20 Kite Pharma Inc

* Kite Pharma announces exclusive license with National Institutes Of Health for multiple Neoantigen Directed T-Cell receptor to treat solid tumors

* Says NIH will receive from Kite an upfront payment and certain clinical, regulatory, and sales milestone payments

* Says NIH will also receive royalties on net sales of products covered by license Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐